Literature DB >> 21063933

Use of genetics in the clinical evaluation and management of heart failure.

Daniel P Judge1, Rosanne Rouf.   

Abstract

OPINION STATEMENT: Inherited forms of cardiomyopathy are common causes of heart failure. Applications of genetics in the evaluation and management of heart failure include the determination of inheritance patterns within families with cardiomyopathy, the evaluation of affected patients for syndromic features, the determination of people within families who are at risk of heart failure, and the identification of responsible gene mutations. Family planning may also be assisted by determination of a clear mutation that predisposes to heart failure. Genetic counseling is critical, and it should accompany the use of genetic testing in cardiovascular diseases. With the rapid pace of growth in technology that is used to determine DNA sequence, costs have declined and clinical application of genetic testing has expanded. This is particularly relevant for heart failure, because each of the familial forms of cardiomyopathy may be caused by a mutation in many different genes. Most families share a unique gene mutation, and appropriate interpretation of novel DNA variants is essential for proper use. The evaluation of risk of arrhythmia in familial forms of heart failure may benefit from genetic testing, as mutations in the genes encoding lamin A/C, desmin, and cardiac troponin T are associated with increased risk of sudden cardiac death. Because of its complexity and the rapid rate of change in available genetic testing options, the genetic evaluation of heart failure is best suited to tertiary referral centers with specific expertise in this area.

Entities:  

Year:  2010        PMID: 21063933     DOI: 10.1007/s11936-010-0092-7

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  53 in total

Review 1.  DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.

Authors:  Sarah Wordsworth; José Leal; Edward Blair; Rosa Legood; Kate Thomson; Anneke Seller; Jenny Taylor; Hugh Watkins
Journal:  Eur Heart J       Date:  2010-03-18       Impact factor: 29.983

2.  The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy.

Authors:  V V Michels; P P Moll; F A Miller; A J Tajik; J S Chu; D J Driscoll; J C Burnett; R J Rodeheffer; J H Chesebro; H D Tazelaar
Journal:  N Engl J Med       Date:  1992-01-09       Impact factor: 91.245

3.  Individual genomes on the horizon.

Authors:  Richard P Lifton
Journal:  N Engl J Med       Date:  2010-03-10       Impact factor: 91.245

4.  Natural history of dilated cardiomyopathy due to lamin A/C gene mutations.

Authors:  Matthew R G Taylor; Pamela R Fain; Gianfranco Sinagra; Misi L Robinson; Alastair D Robertson; Elisa Carniel; Andrea Di Lenarda; Teresa J Bohlmeyer; Debra A Ferguson; Gary L Brodsky; Mark M Boucek; Jean Lascor; Andrew C Moss; Wai Lun P Li; Gary L Stetler; Francesco Muntoni; Michael R Bristow; Luisa Mestroni
Journal:  J Am Coll Cardiol       Date:  2003-03-05       Impact factor: 24.094

5.  On lumpers and splitters, or the nosology of genetic disease.

Authors:  V A McKusick
Journal:  Perspect Biol Med       Date:  1969       Impact factor: 1.416

Review 6.  Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy.

Authors:  L Mestroni; B Maisch; W J McKenna; K Schwartz; P Charron; C Rocco; F Tesson; A Richter; A Wilke; M Komajda
Journal:  Eur Heart J       Date:  1999-01       Impact factor: 29.983

7.  Mutations in sarcomere protein genes in left ventricular noncompaction.

Authors:  Sabine Klaassen; Susanne Probst; Erwin Oechslin; Brenda Gerull; Gregor Krings; Pia Schuler; Matthias Greutmann; David Hürlimann; Mustafa Yegitbasi; Lucia Pons; Michael Gramlich; Jörg-Detlef Drenckhahn; Arnd Heuser; Felix Berger; Rolf Jenni; Ludwig Thierfelder
Journal:  Circulation       Date:  2008-05-27       Impact factor: 29.690

8.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.

Authors:  Alan Kadish; Alan Dyer; James P Daubert; Rebecca Quigg; N A Mark Estes; Kelley P Anderson; Hugh Calkins; David Hoch; Jeffrey Goldberger; Alaa Shalaby; William E Sanders; Andi Schaechter; Joseph H Levine
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

Review 9.  Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy.

Authors:  Ray E Hershberger; Jason Cowan; Ana Morales; Jill D Siegfried
Journal:  Circ Heart Fail       Date:  2009-05       Impact factor: 8.790

10.  Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice guideline.

Authors:  Ray E Hershberger; Joann Lindenfeld; Luisa Mestroni; Christine E Seidman; Matthew R G Taylor; Jeffrey A Towbin
Journal:  J Card Fail       Date:  2009-03       Impact factor: 5.712

View more
  1 in total

1.  Targeted next-generation sequencing detects novel gene-phenotype associations and expands the mutational spectrum in cardiomyopathies.

Authors:  Cinzia Forleo; Anna Maria D'Erchia; Sandro Sorrentino; Caterina Manzari; Matteo Chiara; Massimo Iacoviello; Andrea Igoren Guaricci; Delia De Santis; Rita Leonarda Musci; Antonino La Spada; Vito Marangelli; Graziano Pesole; Stefano Favale
Journal:  PLoS One       Date:  2017-07-27       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.